eShowcase: CTSD Version 2.5
CTSD Version 2.5 provides improved data visualization and enhanced user interface
CTSD Version 2.5 provides improved data visualization and enhanced user interface
Phase Forward (Waltham, MA) has released Version 2.5 of its Clinical Trials Signal Detection (CTSD) system. CTSD detects, evaluates, and tracks potential safety signals, which allows biopharmaceutical companies to analyze and classify potential safety signals, develop a product safety profile, and make more informed decisions earlier in the drug development process.
CTSD 2.5 adds an enhanced user interface that features summary displays, data visualization tools, and access to trial data without programming. The user interface's interactive displays facilitate safety review workflow by including patient level drill downs, Lab Trend graphs, an Exposure Summary graph, and Kaplan-Meier plots. It also offers Hy's Law alerts and a full set of Standardized MedDRA Queries (SMQs).
The product is integrated with Phase Forward's Web Submission Data Manager (WebSDM) platform and offers CDISC support.
Phase Forward, (781) 890-7878, www.phaseforward.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
June 10th 2025In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.
